Selected research
Industry Research
Fraxiparine Industry Research Report 2026
Market perspective
The global Fraxiparine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Fraxiparine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Fraxiparine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Fraxiparine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Fraxiparine include Abbott, Eisai Inc, Sanofi S.A, Pfizer, Inc, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd, Mitsubishi Tanabe Pharma Corporation, Bristol-Myers Squibb Company and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Fraxiparine market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Fraxiparine Market by Company
Abbott
Eisai Inc
Sanofi S.A
Pfizer, Inc
GlaxoSmithKline Plc
Teva Pharmaceutical Industries Ltd
Mitsubishi Tanabe Pharma Corporation
Bristol-Myers Squibb Company
Boehringer Ingelheim
Bayer Healthcare AG
Aspen Holdings
Fraxiparine Segment by Type
Anticoagulant
Antithrombotic
Fraxiparine Segment by Application
General Surgery
Orthopaedic Surgery
Others
Fraxiparine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fraxiparine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fraxiparine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fraxiparine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Fraxiparine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Fraxiparine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Fraxiparine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anticoagulant
- Antithrombotic
Applications
- General Surgery
- Orthopaedic Surgery
- Others
Companies covered
- Abbott
- Eisai Inc
- Sanofi S.A
- Pfizer, Inc
- GlaxoSmithKline Plc
- Teva Pharmaceutical Industries Ltd
- Mitsubishi Tanabe Pharma Corporation
- Bristol-Myers Squibb Company
- Boehringer Ingelheim
- Bayer Healthcare AG
- Aspen Holdings
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Fraxiparine Market Size (2021-2032)
- 2.2.2 Global Fraxiparine Sales (2021-2032)
- 2.2.3 Global Fraxiparine Market Average Price (2021-2032)
- 2.3 Fraxiparine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Anticoagulant
- 2.3.3 Antithrombotic
- 2.4 Fraxiparine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 General Surgery
- 2.4.3 Orthopaedic Surgery
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Fraxiparine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Fraxiparine Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Fraxiparine Revenue of Manufacturers (2021-2026)
- 3.4 Global Fraxiparine Average Price by Manufacturers (2021-2026)
- 3.5 Global Fraxiparine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Fraxiparine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Fraxiparine, Product Type & Application
- 3.8 Global Manufacturers of Fraxiparine, Established Date
- 3.9 Global Fraxiparine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott
- 4.1.1 Abbott Company Information
- 4.1.2 Abbott Business Overview
- 4.1.3 Abbott Fraxiparine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Fraxiparine Product Portfolio
- 4.1.5 Abbott Recent Developments
- 4.2 Eisai Inc
- 4.2.1 Eisai Inc Company Information
- 4.2.2 Eisai Inc Business Overview
- 4.2.3 Eisai Inc Fraxiparine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eisai Inc Fraxiparine Product Portfolio
- 4.2.5 Eisai Inc Recent Developments
- 4.3 Sanofi S.A
- 4.3.1 Sanofi S.A Company Information
- 4.3.2 Sanofi S.A Business Overview
- 4.3.3 Sanofi S.A Fraxiparine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi S.A Fraxiparine Product Portfolio
- 4.3.5 Sanofi S.A Recent Developments
- 4.4 Pfizer, Inc
- 4.4.1 Pfizer, Inc Company Information
- 4.4.2 Pfizer, Inc Business Overview
- 4.4.3 Pfizer, Inc Fraxiparine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer, Inc Fraxiparine Product Portfolio
- 4.4.5 Pfizer, Inc Recent Developments
- 4.5 GlaxoSmithKline Plc
- 4.5.1 GlaxoSmithKline Plc Company Information
- 4.5.2 GlaxoSmithKline Plc Business Overview
- 4.5.3 GlaxoSmithKline Plc Fraxiparine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline Plc Fraxiparine Product Portfolio
- 4.5.5 GlaxoSmithKline Plc Recent Developments
- 4.6 Teva Pharmaceutical Industries Ltd
- 4.6.1 Teva Pharmaceutical Industries Ltd Company Information
- 4.6.2 Teva Pharmaceutical Industries Ltd Business Overview
- 4.6.3 Teva Pharmaceutical Industries Ltd Fraxiparine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Teva Pharmaceutical Industries Ltd Fraxiparine Product Portfolio
- 4.6.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 4.7 Mitsubishi Tanabe Pharma Corporation
- 4.7.1 Mitsubishi Tanabe Pharma Corporation Company Information
- 4.7.2 Mitsubishi Tanabe Pharma Corporation Business Overview
- 4.7.3 Mitsubishi Tanabe Pharma Corporation Fraxiparine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Mitsubishi Tanabe Pharma Corporation Fraxiparine Product Portfolio
- 4.7.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
- 4.8 Bristol-Myers Squibb Company
- 4.8.1 Bristol-Myers Squibb Company Company Information
- 4.8.2 Bristol-Myers Squibb Company Business Overview
- 4.8.3 Bristol-Myers Squibb Company Fraxiparine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bristol-Myers Squibb Company Fraxiparine Product Portfolio
- 4.8.5 Bristol-Myers Squibb Company Recent Developments
- 4.9 Boehringer Ingelheim
- 4.9.1 Boehringer Ingelheim Company Information
- 4.9.2 Boehringer Ingelheim Business Overview
- 4.9.3 Boehringer Ingelheim Fraxiparine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Boehringer Ingelheim Fraxiparine Product Portfolio
- 4.9.5 Boehringer Ingelheim Recent Developments
- 4.10 Bayer Healthcare AG
- 4.10.1 Bayer Healthcare AG Company Information
- 4.10.2 Bayer Healthcare AG Business Overview
- 4.10.3 Bayer Healthcare AG Fraxiparine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bayer Healthcare AG Fraxiparine Product Portfolio
- 4.10.5 Bayer Healthcare AG Recent Developments
- 4.11 Aspen Holdings
- 4.11.1 Aspen Holdings Company Information
- 4.11.2 Aspen Holdings Business Overview
- 4.11.3 Aspen Holdings Fraxiparine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Aspen Holdings Fraxiparine Product Portfolio
- 4.11.5 Aspen Holdings Recent Developments
5 Global Fraxiparine Market Scenario by Region
- 5.1 Global Fraxiparine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Fraxiparine Sales by Region: 2021-2032
- 5.2.1 Global Fraxiparine Sales by Region: 2021-2026
- 5.2.2 Global Fraxiparine Sales by Region: 2027-2032
- 5.3 Global Fraxiparine Revenue by Region: 2021-2032
- 5.3.1 Global Fraxiparine Revenue by Region: 2021-2026
- 5.3.2 Global Fraxiparine Revenue by Region: 2027-2032
- 5.4 North America Fraxiparine Market Facts & Figures by Country
- 5.4.1 North America Fraxiparine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Fraxiparine Sales by Country (2021-2032)
- 5.4.3 North America Fraxiparine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Fraxiparine Market Facts & Figures by Country
- 5.5.1 Europe Fraxiparine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Fraxiparine Sales by Country (2021-2032)
- 5.5.3 Europe Fraxiparine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Fraxiparine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Fraxiparine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Fraxiparine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Fraxiparine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Fraxiparine Market Facts & Figures by Country
- 5.7.1 South America Fraxiparine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Fraxiparine Sales by Country (2021-2032)
- 5.7.3 South America Fraxiparine Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Fraxiparine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Fraxiparine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Fraxiparine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Fraxiparine Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Fraxiparine Sales by Type (2021-2032)
- 6.1.1 Global Fraxiparine Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Fraxiparine Sales Market Share by Type (2021-2032)
- 6.2 Global Fraxiparine Revenue by Type (2021-2032)
- 6.2.1 Global Fraxiparine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Fraxiparine Revenue Market Share by Type (2021-2032)
- 6.3 Global Fraxiparine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Fraxiparine Sales by Application (2021-2032)
- 7.1.1 Global Fraxiparine Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Fraxiparine Sales Market Share by Application (2021-2032)
- 7.2 Global Fraxiparine Revenue by Application (2021-2032)
- 7.2.1 Global Fraxiparine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Fraxiparine Revenue Market Share by Application (2021-2032)
- 7.3 Global Fraxiparine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Fraxiparine Value Chain Analysis
- 8.1.1 Fraxiparine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Fraxiparine Production Mode & Process
- 8.2 Fraxiparine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Fraxiparine Distributors
- 8.2.3 Fraxiparine Customers
9 Global Fraxiparine Analyzing Market Dynamics
- 9.1 Fraxiparine Industry Trends
- 9.2 Fraxiparine Industry Drivers
- 9.3 Fraxiparine Industry Opportunities and Challenges
- 9.4 Fraxiparine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst